Treder; Martin
Patent Applications and Registrations
Patent applications and USPTO patent grants for Treder; Martin.The latest application filed is for "tandem diabody for cd16a-directed nk-cell engagement".
- Treder; Martin - Reilingen DE
- TREDER; Martin - Heidelberg DE
- TREDER; MARTIN - ZUERICH CH
- Treder; Martin - Martinsried DE
- Treder; Martin - Zurich CH
- Treder; Martin - Munchen N/A DE
| Patent | Date |
|---|---|
| Antibodies directed to HER-3 and uses thereof Grant 11,267,900 - Rothe , et al. March 8, 2 | 2022-03-08 |
| Tandem Diabody for CD16A-directed NK-cell Engagement App 20220041717 - ROSS; Thorsten ; et al. | 2022-02-10 |
| Tandem diabody for CD16A-directed NK-cell engagement Grant 11,180,558 - Ross , et al. November 23, 2 | 2021-11-23 |
| Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy Grant 11,167,029 - Treder , et al. November 9, 2 | 2021-11-09 |
| Uses Of Nk Cell Engaging Antibody Fusion Constructs For Treatments App 20210253698 - Tesar; Michael ; et al. | 2021-08-19 |
| Cryopreserved NK cells preloaded with an antibody construct App 20210169936 - REUSCH; Uwe ; et al. | 2021-06-10 |
| NK cell engaging antibody fusion constructs Grant 11,001,633 - Tesar , et al. May 11, 2 | 2021-05-11 |
| Bispecific Egfr/cd16 Antigen-binding Protein App 20200405833 - Kluge; Michael ; et al. | 2020-12-31 |
| Nk Cell Engaging Antibody Fusion Constructs App 20200109202 - Tesar; Michael ; et al. | 2020-04-09 |
| Combination Of An Anti-cd16a Antibody With A Cytokine App 20200010547 - Koch; Joachim ; et al. | 2020-01-09 |
| Tandem Diabody for CD16A-directed NK-cell Engagement App 20190345249 - Ross; Thorsten ; et al. | 2019-11-14 |
| Antibodies Directed To Her-3 And Uses Thereof App 20190263930 - ROTHE; MIKE ; et al. | 2019-08-29 |
| Activated HER3 as a marker for predicting therapeutic efficacy Grant 10,365,283 - Rothe , et al. July 30, 2 | 2019-07-30 |
| Multivalent Fv Antibodies App 20190040155 - ELLWANGER; Kristina ; et al. | 2019-02-07 |
| Combination therapy including tumor associated antigen binding antibodies App 20180353603 - Esslinger; Christoph ; et al. | 2018-12-13 |
| Antibodies directed to HER-3 and uses thereof Grant 10,100,124 - Rothe , et al. October 16, 2 | 2018-10-16 |
| Combination Of A Cd30xcd16 Antibody With A Pd-1 Antagonist For Therapy App 20180085456 - TREDER; Martin ; et al. | 2018-03-29 |
| Antibodies Directed To Her-3 And Uses Thereof App 20160168264 - ROTHE; MIKE ; et al. | 2016-06-16 |
| Activated Her3 As A Marker For Predicting Therapeutic Efficacy App 20160161491 - ROTHE; Mike ; et al. | 2016-06-09 |
| Antibodies directed to HER-3 and uses thereof Grant 9,249,230 - Rothe , et al. February 2, 2 | 2016-02-02 |
| Antibodies directed to HER-3 and uses thereof Grant 8,771,695 - Rothe , et al. July 8, 2 | 2014-07-08 |
| Magea3 Binding Antibodies App 20140186363 - Esslinger; Christoph ; et al. | 2014-07-03 |
| Magea3 Binding Antibodies App 20140093514 - Esslinger; Christoph ; et al. | 2014-04-03 |
| Combination Therapy Including Tumor Associated Antigen Binding Antibodies App 20130295091 - Esslinger; Christoph ; et al. | 2013-11-07 |
| Antibodies Directed to HER-3 and Uses Thereof App 20120058122 - Rothe; Mike ; et al. | 2012-03-08 |
| Antibodies Directed to HER-3 and Uses Thereof App 20100183631 - Rothe; Mike ; et al. | 2010-07-22 |
| Antibodies directed to HER-3 and uses thereof Grant 7,705,130 - Rothe , et al. April 27, 2 | 2010-04-27 |
| Activated Her3 As A Marker For Predicting Therapeutic Efficacy App 20100047829 - Rothe; Mike ; et al. | 2010-02-25 |
| Antibodies directed to HER-3 and uses thereof App 20080124345 - Rothe; Mike ; et al. | 2008-05-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 